Summary The coronavirus disease 2019 (COVID‐19) pandemic is a rapidly evolving global
emergency that continues to strain healthcare systems. Emerging research describes a …

Outcomes for patients with hematologic malignancy infected with COVID-19 have not been
aggregated. The objective of this study was to perform a systematic review and meta …

As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically
needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we …

Background Data on patients with COVID-19 who have cancer are lacking. Here we
characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify …

Patients with cancer have high mortality from coronavirus disease 2019 (COVID-19), and the
immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 …

Abstract As of 10 April 2020, New York State had 180,458 cases of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and 9,385 reported deaths. Patients with cancer …

Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant morbidity and …

Background Haematopoietic stem-cell transplantation (HSCT) recipients are considered at
high risk of poor outcomes after COVID-19 on the basis of their immunosuppressed status …

Background Patients with coronavirus disease 2019 (COVID-19) who have underlying
malignancy have a higher mortality rate compared with those without cancer, although the …

Background This study applies an umbrella review approach to summarise the global
evidence on the risk of severe COVID-19 outcomes in patients with pre-existing health …